# Judge — L4-TICK6-LEADER — iter 1

Judge: Kimi K3. Not the author of this increment. Mood: critic.
File under review: `src/content/blog/best-peptide-for-weight-loss-2026.mdx` (body + sources YAML read in full, not the tick log).
Independent re-fetch this run: `efetch.fcgi?db=pubmed&id=27295427&rettype=abstract&retmode=text` (fetched 2026-09-02, full record read).

## Identifier check (first, because everything hangs on it)

Fetched record: **N Engl J Med. 2016 Jul 28;375(4):311-22. doi:10.1056/NEJMoa1603827.** Title: "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." Marso SP et al.; LEADER Steering Committee; LEADER Trial Investigators. Funded by Novo Nordisk / NIH; ClinicalTrials.gov **NCT01179048**. PMCID PMC4985288.

This is the **2016 NEJM primary publication**, not a secondary LEADER analysis (no "renal outcomes," "microvascular," or subgroup subtitle). Title, trial name, NCT, DOI all match the sources YAML entry exactly. **Not a sibling-trial mixup.**

## Criterion-by-criterion

| # | Criterion | Verdict | What I read |
|---|---|---|---|
| 1 | PMID 27295427 attached, figures quoted accurately | **PASS** | Body line ~172: "9340 adults … median follow-up 3.8 years … 608 of 4668 patients (13.0%) … 694 of 4672 (14.9%) … hazard ratio 0.87; 95% CI 0.78 to 0.97; P=0.01 for superiority". Abstract: "A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. … 608 of 4668 patients [13.0%] … 694 of 4672 [14.9%] (hazard ratio, 0.87; 95% CI, 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority)". Every digit matches the fetched abstract. Sources YAML carries pmid, doi 10.1056/NEJMoa1603827, nctId NCT01179048, verifiedAt 2026-09-02. |
| 2 | No rounded "13% reduction" headlined without the HR | **PASS** | Grep `13%` on the file: no match. The only "13.0%" is the event rate, quoted alongside 14.9%, HR, CI, and P. The headline statistic is the HR, not a relative-risk slogan. (The "−13.7%" elsewhere in the file is the SURMOUNT-5 semaglutide arm under pmid-40353578 — a different, separately judged citation.) |
| 3 | No milligram dose copied | **PASS** | The LEADER bullet contains no dose. The fetched abstract does not state one (1.8 mg lives in full-text METHODS only); nothing was transcribed from memory. |
| 4 | Liraglutide dossier untouched | **PASS** | `git status --short` and `git diff --stat` on `src/content/peptides/liraglutide.mdx`: empty. Dossier not reopened, per the tick note. |
| 5 | No new URLs | **PASS** | File pre-exists (created 7a77f5e, 2026-02). Diff is body/frontmatter only. No new slug, no 301, no new route. The added waitlist line links to existing `/newsletter`. |
| 6 | OSA 63% / TRIUMPH 28.7% not restored | **PASS** | Grep `OSA|sleep apnea|28\.7|63%`: no matches. The uncommitted diff *removes* the old "TRIUMPH-4 Phase 3: 28.7%" bullet and the "A 28.7% weight loss in Phase 3" takeaway, replacing them with an explicit "this page does not quote TRIUMPH efficacy percentages." The "63.2%" present in the SCALE bullet is the SCALE ≥5% responder rate under pmid-26132939 — different trial, different number, out of this loop's scope. |
| 7 | Estimand integrity (L4: efficacy estimand not headlined) | **PASS** | LEADER's primary time-to-event composite is quoted as published: event counts, HR, CI, superiority P. The P<0.001 noninferiority co-result is omitted; that is truncation, not distortion — the superiority claim is the stronger, abstract-stated result. |
| 8 | Identifier was fetched, not worklist-recycled | **PASS** | Tick log shows esearch `Marso[Author] AND liraglutide[Title] AND 2016[pdat] AND "N Engl J Med"[Journal]` → efetch. My independent efetch reproduces every quoted figure. Resolution-only is not being offered as topical proof; the quote itself is the proof. |

## Scope note

The uncommitted diff on this file also contains earlier-tick work (SURMOUNT-5 re-attach to 40353578, SCALE 26132939, REDEFINE-1 40544433, FDA first-generic source, waitlist CTA). Those belong to other loops/judges; I score only the LEADER attach here. Nothing in the shared diff sabotages this increment.

## Gaming check

The implementer's claims are narrow and falsifiable, and they survive falsification: I re-fetched the PMID myself and every quoted number is in the abstract verbatim. The tick log is explicitly labeled "not a KEEP" and does not ask me to rubber-stamp it. No self-marked pass was found and none was accepted. The one cosmetic discrepancy — `verifiedAt: '2026-09-02'` inside a `runs/2026-09-01/` folder — reflects the real fetch date and changes nothing. The strongest available criticism is omission of the P<0.001 noninferiority result, but quoting the superiority P alone is standard and the HR/CI carry the full picture. No gaming detected.

## Verdict

**KEEP.**

One-line summary for the ratchet log: LEADER (PMID 27295427, NEJM 2016 primary, NCT01179048) attached to `best-peptide-for-weight-loss-2026.mdx` with abstract-verbatim n=9340, 3.8 y median follow-up, 608/4668 (13.0%) vs 694/4672 (14.9%), HR 0.87 (0.78–0.97), P=0.01 superiority; no dose, no rounded-percent headline, dossier untouched, no new URLs.
